Merck & Co., Inc. Sees Unusually Large Options Volume (NYSE:MRK)

Merck & Co., Inc. (NYSE:MRK) was the recipient of some unusual options trading on Monday. Traders purchased 227,658 call options on the company. This is an increase of approximately 784% compared to the average daily volume of 25,755 call options.

Insider Activity

In related news, EVP David Williams sold 52,847 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Richard R. Deluca sold 11,699 shares of the stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total value of $1,539,939.37. Following the completion of the sale, the executive vice president owned 110,167 shares of the company’s stock, valued at approximately $14,501,282.21. This trade represents a 9.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last 90 days. 0.17% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds have recently modified their holdings of the stock. Bullseye Investment Management LLC acquired a new position in shares of Merck & Co., Inc. in the 2nd quarter valued at $27,000. Talon Private Wealth LLC acquired a new stake in Merck & Co., Inc. during the 2nd quarter worth about $995,000. Marathon Wealth Advisors LLC lifted its stake in Merck & Co., Inc. by 1.0% during the second quarter. Marathon Wealth Advisors LLC now owns 20,801 shares of the company’s stock valued at $2,673,000 after buying an additional 205 shares in the last quarter. Bouchey Financial Group Ltd. boosted its holdings in shares of Merck & Co., Inc. by 13.7% in the second quarter. Bouchey Financial Group Ltd. now owns 3,672 shares of the company’s stock worth $475,000 after buying an additional 442 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Merck & Co., Inc. by 12.3% in the second quarter. The Manufacturers Life Insurance Company now owns 2,073,176 shares of the company’s stock worth $266,403,000 after buying an additional 227,589 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of Merck & Co., Inc. stock traded up $0.89 during trading on Monday, hitting $144.82. 7,380,852 shares of the stock were exchanged, compared to its average volume of 10,723,884. The stock’s fifty day moving average is $136.51 and its 200 day moving average is $124.41. The stock has a market cap of $357.30 billion, a PE ratio of 115.86, a P/E/G ratio of 6.26 and a beta of 0.21. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on MRK shares. Wells Fargo & Company lifted their price target on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research note on Friday, September 4th. Wolfe Research boosted their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. Argus upped their target price on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 25th. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, UBS Group lifted their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Seventeen research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $151.32.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.